Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

G3798

Sigma-Aldrich

10074-G5

≥98% (HPLC)

Synonym(s):

Biphenyl-2-yl-(7-nitrobenzo[1,2,5]oxadiazol-4-yl)amine, N-2-Biphenylyl-7-nitro-2,1,3-benzoxadiazol-4-amine, N-[1,1′-Biphenyl-2-yl]-7-nitro-2,1,3-Benzoxadiazol-4-amine

Sign Into View Organizational & Contract Pricing

Select a Size

50 G
$1,040.60
250 G
$3,509.00
1 KG
$7,247.90

$1,040.60

Estimated to ship onMay 17, 2025

Request a Bulk Order
All Photos(1)

Select a Size

Change View
50 G
$1,040.60
250 G
$3,509.00
1 KG
$7,247.90

About This Item

Empirical Formula (Hill Notation):
C18H12N4O3
CAS Number:
413611-93-5
Molecular Weight:
332.31
MDL number:
MFCD00576774
UNSPSC Code:
12352200
PubChem Substance ID:
329799918
NACRES:
NA.77

$1,040.60

Estimated to ship onMay 17, 2025

Request a Bulk Order

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

red

solubility

DMSO: >10 mg/mL

storage temp.

room temp

SMILES string

[O-][N+](=O)c1ccc(Nc2ccccc2-c3ccccc3)c4nonc14

InChI

1S/C18H12N4O3/c23-22(24)16-11-10-15(17-18(16)21-25-20-17)19-14-9-5-4-8-13(14)12-6-2-1-3-7-12/h1-11,19H

InChI key

KMJPYSQOCBYMCF-UHFFFAOYSA-N

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
G327250950PHG0006
Guanidina hydrochloride BioUltra, for molecular biology, ≥99.5% (AT)

50933

Guanidina hydrochloride

Guanidina hydrochloride for molecular biology, ≥99%

G3272

Guanidina hydrochloride

Guanidina hydrochloride ≥98%

50950

Guanidina hydrochloride

Guanidina hydrochloride

PHG0006

Guanidina hydrochloride

grade

for molecular biology

grade

for molecular biology

grade

-

grade

-

assay

≥99.5% (AT)

assay

≥99%

assay

≥98%

assay

-

product line

BioUltra

product line

-

product line

-

product line

-

Quality Level

200

Quality Level

400

Quality Level

200

Quality Level

400

form

powder or crystals

form

crystalline powder

form

powder or crystals

form

powder

Biochem/physiol Actions

10074-G5 is a c-Myc/Max interaction inhibitor. The c-Myc oncoprotein and its partner Max are intrinsically disordered (ID) monomers that undergo coupled folding and binding upon heterodimerization. 10074-G5, similarly to 10058-F4 (#F3680), specifically inhibits this interaction by binding to c-Myc, thus preventing C-Myc specific DNA binding and target genes regulation. 10074-G5 (2.8 microM) is slightly more potent that 10058-F4 (5.2 microM). It was discovered that 10074-G5 binds to a different specific binding site (region) of C-Myc than 10054-F4. Thus, the compound may become desirable for probing different interactions.

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

  • Specification Sheet

    • Choose from one of the most recent versions:

    Certificates of Analysis (COA)

    Lot/Batch Number
    114M4615V
    061M4604V
    059K47122
    059K47121
    059K4712

    Don't see the Right Version?

    If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

    Search for a COA

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    Chengsheng Wu et al.
    BMC cancer, 18(1), 361-361 (2018-04-04)
    The phenomenon that malignant cells can acquire stemness under specific stimuli, encompassed under the concept of cancer cell plasticity, has been well-described in epithelial malignancies. To our knowledge, cancer cell plasticity has not yet been described in hematopoietic cancers. To
    Quan Yang et al.
    Frontiers in immunology, 12, 627072-627072 (2021-03-13)
    The accumulation of myeloid-derived suppressor cells (MDSCs) is one of the major obstacles to achieve an appropriate anti-tumor immune response and successful tumor immunotherapy. MDSCs in tumor-bearing hosts are primarily polymorphonuclear (PMN-MDSCs). However, the mechanisms regulating the development of MDSCs
    Alina Castell et al.
    Scientific reports, 8(1), 10064-10064 (2018-07-04)
    MYC is a key player in tumor development, but unfortunately no specific MYC-targeting drugs are clinically available. MYC is strictly dependent on heterodimerization with MAX for transcription activation. Aiming at targeting this interaction, we identified MYCMI-6 in a cell-based protein
    Udom Lao-On et al.
    Biochimica et biophysica acta. Molecular basis of disease, 1866(3), 165656-165656 (2019-12-25)
    Here we showed that the c-Myc oncogene is responsible for overexpression of pyruvate carboxylase (PC) in highly invasive MDA-MB-231 cells. Pharmacological inhibition of c-Myc activity with 10074-G5 compound, resulted in a marked reduction of PC mRNA and protein, concomitant with
    Huabo Wang et al.
    Oncotarget, 6(18), 15857-15870 (2015-06-04)
    The c-Myc (Myc) oncoprotein is deregulated in a large proportion of diverse human cancers. Considerable effort has therefore been directed at identifying pharmacologic inhibitors as potential anti-neoplastic agents. Three such groups of small molecule inhibitors have been described. The first
    View All Related Papers

    Articles

    Oncogenes and Tumor Suppressors Reprogram Metabolism

    We present an article about how proliferating cells require the biosynthesis of structural components for biomass production and for genomic replication.

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service